- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7233
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients ; day:14 ; month:9 ; year:2020 ; pages:1-6
Cancer and metastasis reviews ; (14.9.2020), 1-6
- Urheber
-
Nakajima, Kosei
Balan, Vitaly
Raz, Avraham
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10555-020-09932-4
- URN
-
urn:nbn:de:101:1-2020110222263110515591
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nakajima, Kosei
- Balan, Vitaly
- Raz, Avraham
- SpringerLink (Online service)
Ähnliche Objekte (12)
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
TrkB-target Galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
TrkB-target Galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
TrkB-target Galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target